Intraocular Povidone Iodine During Pars Plana Vitrectomy for Severe and Atypical Endophthalmitis

BACKGROUND AND OBJECTIVE: To describe the experience and clinical outcomes of povidone iodine (PI) infusion in the setting of pars plana vitrectomy for the treatment of endophthalmitis

Bibliographische Detailangaben
Veröffentlicht in:Ophthalmic surgery, lasers & imaging retina. - 2013. - 52(2021), 9 vom: 03. Sept., Seite 485-490
1. Verfasser: Mi, Xiaofan (VerfasserIn)
Weitere Verfasser: Malbin, Brett, Lin, Xihui
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2021
Zugriff auf das übergeordnete Werk:Ophthalmic surgery, lasers & imaging retina
Schlagworte:Journal Article Povidone-Iodine 85H0HZU99M
Beschreibung
Zusammenfassung:BACKGROUND AND OBJECTIVE: To describe the experience and clinical outcomes of povidone iodine (PI) infusion in the setting of pars plana vitrectomy for the treatment of endophthalmitis
MATERIALS AND METHODS: This was a retrospective case series of 12 patients with clinical and/or culture evidence of endophthalmitis requiring pars plana vitrectomy with 0.025% PI used in vitreous irrigation solution during vitrectomy. The primary endpoint was clinical resolution of the infection. Secondary endpoints included visual recovery, need for repeat surgery, and ocular toxicity RESULTS: There were 11 eyes that showed clinical or culture evidence of resolution of infection postoperatively (91.7%); 10 eyes had improvement in vision postoperatively (83.3%). Overall uncorrected visual acuity improved from 20/5321 (2.43 ± 0.58 logMAR) to 20/375 (1.27 ± 1.05 logMAR) (P = .0003). No clinical evidence of ocular toxicity or unexplained vision loss due to PI was observed
CONCLUSIONS: PI infusion during pars plana vitrectomy for endophthalmitis appears safe and led to excellent post-surgical results in a traditionally high-risk cohort. [Ophthalmic Surg Lasers Imaging Retina. 2021;52:485-490.]
Beschreibung:Date Completed 24.11.2021
Date Revised 24.11.2021
published: Print-Electronic
Citation Status MEDLINE
ISSN:2325-8179
DOI:10.3928/23258160-20210820-01